Altimmune Outlines Pemvidutide Plans In MASH And Beyond

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Liver care
Altimmune will study its MASH candidate in alcohol-related liver disease • Source: Shutterstock

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the dual GLP-1/glucagon receptor agonist’s reach far beyond its most advanced indications of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Key Takeaways
  • Altimmune made a case for its dual GLP-1/glucagon receptor agonist pemvidutide in multiple diseases at an investor day, including MASH and obesity.

The company described the drug as Phase III-ready in obesity, soon to report Phase IIb histology data in MASH and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Therapy Areas